Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tole
AIM ImmunoTech reports no serious adverse events in dosing of Cohort 1 in Phase 1 study of Ampligen drug's safety as an intranasal therapy
10:29am, Wednesday, 07'th Apr 2021
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no seri
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's dru
AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus
04:27pm, Wednesday, 31'st Mar 2021
Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of
AIM ImmunoTech headed in 2021 with $54.4M in capital as it advances Ampligen to treat COVID-19 and cancer
12:49pm, Wednesday, 31'st Mar 2021
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that it ended 2020 with cash, cash equivalents, and marketable securities of $54.4 million. That's a sizable increase compared to the $8.8 m
AIM ImmunoTech Reports 2020 Year-End Financial Results
09:15am, Wednesday, 31'st Mar 2021
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.
AIM ImmunoTech announces addition of single-agent Ampligen arm to ongoing study of cancer patients with coronavirus
11:04am, Monday, 22'nd Mar 2021
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Park's ongoing Ph
8 Biotech Penny Stocks for Investors to Watch
11:54am, Wednesday, 10'th Mar 2021
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
06:55am, Wednesday, 10'th Mar 2021
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM's Chief Executive Officer, has been invited to present at the Inaugu
AIM ImmunoTech doses first healthy subject in intranasal Ampligen coronavirus study
10:19am, Monday, 08'th Mar 2021
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Monday that it has dosed the first healthy subjects in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for the coronavirus (CVO
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
09:15am, Monday, 08'th Mar 2021
Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases Marks important milestone towards development of Amp
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
06:50am, Thursday, 04'th Mar 2021
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
01:57pm, Wednesday, 24'th Feb 2021
AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as
AIM ImmunoTech developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too
12:22pm, Wednesday, 24'th Feb 2021
Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that its subsidiary NV Hemispherx Biopharma Europe has received formal notification from the European Commission approving the company's Orpha
